on Theranexus (EPA:ALTHX)
THX Pharma increases the resources of its liquidity contract
On February 25, 2026, THX Pharma, a biopharmaceutical specialist in rare neurological diseases, announced a financial boost to its liquidity contract. This contract, managed by Portzamparc – BNP Paribas, now benefits from an additional cash injection of €100,000.
Since this transaction, the contract's assets amount to 31,613 THX PHARMA shares and €166,838.99. By comparison, as of December 31, 2025, the contract held 37,142 shares and €42,872.78 in cash.
This initiative aims to optimize support for the liquidity of the company's securities, which are listed on the Euronext Growth market in Paris.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news